AzTrials
AzTrials

Gastric Cancer/Gastroesophageal Junction AdenocarcinomaPhase 2NCT06091423

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

A Phase 2 study testing XELOX combined with Fruquintinib and Sintilimab in people with Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, run by Xiaofeng Chen at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Gastric cancer is the third leading cause of morbidity and mortality among malignant tumors in China, and less than 30% of patients can be cured by surgery. Liver metastasis, retroperitoneal lymph node metastasis and peritoneal metastasis are the most common metastatic sites of gastric cancer, which are also the… Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
XELOX combined with Fruquintinib and Sintilimab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
43 participants
Where
1 siteChina
Study dates
25 Oct 2023to 25 Nov 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age: 18-75 years of age;
  • Understand the steps and content, and written informed consent signed voluntarily;
  • Is confirmed by histopathology and/or cytology her2-negative or HER2 status unknown late recurrence or stomach esophagus stomach/integration of adenocarcinoma;
  • In this research to define transfer of oligonucleotides definition: the primary lesion and regional lymph node metastasis of process to determine the surgeon can be cut or boundary can be cut, only intrahepatic metastasis and distant metastasis (metastases number 5 or less, a single lesion or less 5 cm in diameter.) And or retroperitoneal lymph node metastasis (16a2,16b1,16a1,16b2 metastasis), no other distant metastasis;
  • At least one measurable lesion according to RECIST 1.1 criteria;
  • No previous treatment with VEGFR-targeted drugs and PD-1/PD-L1 monoclonal antibodies. Patients who had relapsed more than 6 months after the completion of postoperative adjuvant chemotherapy with platinum or paclitaxel or fluorouracil and had no grade 2 or higher toxicity were eligible for enrollment.
Show all 10Show fewer
  • ECOG PS score: 0-1;
  • Expected survival time ≥3 months;
  • The main viscera function is good, namely into groups of related within 14 days before check index meet the following requirements:
  • hemoglobin ≥80 g/L; (2) neutrophil count >1.5×109/L; (3) platelet count ≥80×109/L; (4) Total bilirubin ≤2.5×ULN (upper limit of normal); (5) serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5×ULN; (6) the endogenous creatinine clearance or 60 ml/min (Cockcroft - Gault formula); (7) Echocardiography: left ventricular ejection fraction (LVEF)≥50%; (8) Thyroid function indexes: thyroid stimulating hormone (TSH) and free thyroxine (FT3/FT4) were in the normal range or only mildly abnormal, without related clinical symptoms; (9) A body weight of 40 kg or more, or a BMI > 18.5;

Who cannot join

  • Patients with other malignant tumors in the past or at the same time, but have been cured of early tumors, including basal cell carcinoma of the skin and carcinoma in situ of the cervix, stage I lung cancer, stage I colorectal cancer and other tumors that do not affect the patient's life in the short term according to the investigator's judgment can be excluded;
  • Participated in other drug clinical trials within four weeks;
  • Multiple factors affecting oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
  • Patients with a history of bleeding and any bleeding events of CTCAE5.0 grade 3 or higher within 4 weeks before screening;
  • Metastasis in other distant sites, including but not limited to lung metastasis, brain metastasis, bone metastasis, distant lymph node metastasis, and peritoneal metastasis;
  • Patients with hypertension not well controlled by single antihypertensive medication (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg); Patients with a history of unstable angina; Newly diagnosed angina pectoris within 3 months before screening or myocardial infarction within 6 months before screening; Arrhythmias (including QTcF ≥450 ms in men and ≥470 ms in women) required long-term use of antiarrhythmic drugs and New York Heart Association (NYHA) grade ≥II cardiac dysfunction;
Show all 19Show fewer
  • Long-term unhealed wounds or incompletely healed fractures;
  • Imaging shows that the tumor has invaded the important blood vessels or the investigator judges that the patient's tumor has a high possibility of invading the important blood vessels during the treatment and causing fatal hemorrhage;
  • Abnormal coagulation function, with bleeding tendency (14 days before enrollment must meet: INR in the normal range without anticoagulant or clinically insignificant abnormality); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogues; International standardization in prothrombin time ratio (INR) under the premise of 1.5 or less, allowing purpose to prevent the use of low-dose warfarin (1 mg orally, once per day) or low-dose aspirin (amount does not exceed 100 mg daily);
  • Occurrence of arterial/venous thrombosis events within 6 months before screening, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis (except for venous thrombosis caused by venous catheterization due to previous chemotherapy and judged by investigators to be cured), and pulmonary embolism;
  • Urine routine showed urine protein ≥++ and confirmed 24-hour urine protein quantitation >1.0 g;
  • Previous use of immune-targeted therapy drugs;
  • Have a history of immunodeficiency or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
  • Patients with infectious pneumonia, non-infectious pneumonia, interstitial pneumonia and other patients requiring corticosteroids;
  • A history of severe chronic autoimmune diseases, such as systemic lupus erythematosus; He had a history of inflammatory bowel disease such as ulcerative enteritis, Crohn's disease, and a history of chronic diarrhea such as irritable bowel syndrome. A history of sarcoidosis or tuberculosis; Patients with a history of active hepatitis B or C, and HIV infection; Good control of severe autoimmune disease, such as dermatitis, arthritis, psoriasis, etc can be into the group. Patients with hepatitis B virus titer <1000copy/ml were eligible for enrollment.
  • Patients with hypersensitivity to human or murine monoclonal antibodies;
  • Have a history of psychotropic drug abuse and cannot quit or have mental disorders;
  • Patients who do not follow the doctor's advice, do not follow the prescribed medication, or have incomplete data, which may affect the efficacy or safety judgment;
  • Concomitant diseases that, in the judgment of the investigator, seriously compromise patient safety or interfere with patient completion of the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Chen xiao feng, Ph.D contact

13585172066

chenxiaofengnjmu@163.com

China1 site, 1 recruiting

  • Jiangsu Province Hospita

    Nanjin

    Chen xiao feng, 13585172066, chenxiaofengnjmu@163.com

    Recruiting

Other trials in China

About this study

Official title: XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study ( FISSION Study )

Gastric cancer is the third leading cause of morbidity and mortality among malignant tumors in China, and less than 30% of patients can be cured by surgery. Liver metastasis, retroperitoneal lymph node metastasis and peritoneal metastasis are the most common metastatic sites of gastric cancer, which are also the important causes of death. Improve the conversion of oligonucleotides transfer patients resection rate, prolonged progression-free survival of these patients, is an important direction to improve survival of patients with advanced gastric cancer;

This study was a prospective, single-arm, multi-center clinical study. We plan to treat patients with gastric cancer/gastroesophageal junction adenocarcinoma with liver and/or retroperitoneal lymph node metastasis only with XELOX regimen + fruquinitinib + sintilimab for 4-6 cycles before surgery/ablation conversion therapy to achieve tumor-free status as far as possible. To explore the value of conversion therapy in patients with intrahepatic oligometastasis of gastric cancer.

Being tested
XELOX combined with Fruquintinib and Sintilimab
Medical subject headings
Stomach Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • XELOX combined with Fruquintinib and SintilimabDrug

    XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w

Study groups in NCT06091423
Study groupRoleWhat they receive
ExperimentalExperimentalXELOX combined with Fruquintinib and Sintilimab
Receives: Drug: XELOX combined with Fruquintinib and Sintilimab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression free survival (PFS)

    Time from randomization to disease progression or death from any cause

    Measured: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year]

Secondary outcomes (6)

  1. Overall survival (OS）

    Overall survival means any reason from patients into groups to the date of death

    Measured: from randomization until death due to any cause, assessed up to 3 year

  2. Objective response rate (ORR)

    the proportion of patients with complete response or partial response, using RECIST v 1.1.

    Measured: Time Frame: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

  3. Disease Control Rate (DCR)

    the proportion of patients with complete response, partial response or stable disease, using RECIST v 1.1.

    Measured: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

  4. Duration of Response (DOR)

    Cancer for the first time that assessment for CR or PR to the first evaluation for PD or any cause the time of death.

    Measured: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year

  5. translational rate

    It refers to the proportion of all enrolled patients who underwent radical surgery/ablation therapy after medical treatment.

    Measured: 2-3 months

  6. Adverse event (AEs)

    Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. The number of Participants with adverse events will be recorded at each treatment visit.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Oct 2023
  2. Study start25 Oct 2023
  3. Primary completion25 Nov 2025 (estimated)
  4. Study completion25 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
43 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06091423
Sponsor's protocol ID
Fission
Status last verified
Nov 2023
First submitted
10 Oct 2023
Last updated
30 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing XELOX combined with Fruquintinib and Sintilimab in people with Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, run by Xiaofeng Chen at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Chen xiao feng, Ph.D (13585172066, chenxiaofengnjmu@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression free survival (PFS) (time frame: from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year]). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06091423.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in